Biolex Therapeutics Researchers Present Locteron® U.S. Phase 2a Hepatitis C Trial Results at EASL Conference
Biolex Therapeutics, Inc. announced that the results from its United States Phase 2a clinical trial (the "PLUS" trial) of Locteron® will be presented today at the 44th Annual Meeting of the European Association for the Study of the Liver (EASL) in Copenhag... [more]
